Xo­lair PBS for CSU

Pharmacy Daily - - FRONT PAGE -

THE first and only medicine ap­proved to treat se­vere Chronic Spon­ta­neous Ur­ti­caria (CSU) will be added to the Phar­ma­ceu­ti­cal Ben­e­fits Scheme (PBS) to­mor­row, 01 Sep.

The PBS list­ing of the bi­o­logic medicine Xo­lair (oma­l­izumab) is for adults and ado­les­cents (12 years of age and above) with se­vere CSU who re­main symp­to­matic de­spite stan­dard ther­apy.

Camp­bell­town Hospi­tal Im­munol­ogy and Al­lergy unit head Pro­fes­sor Con­nie Kate­laris wel­comed the list­ing say­ing, “There has been a sig­nif­i­cant treat­ment gap for those liv­ing with an­ti­his­tamine-re­sis­tant CSU”.

“Xo­lair of­fers pa­tients an ef­fec­tive method of man­ag­ing CSU as an al­ter­na­tive to cor­ti­cos­teroid use,” she added.

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.